As both responders and non‐responders contained comparable proportions of lung cancer‐specific CD4 and CD8 T cells in our cohort of patients before the start of therapy, the experimental evidence pointed to the baseline intrinsic functionality of CD4 immunity as the key factor in our study. The gene discussed is CD4; the disease is lung cancer.